Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Predictors of Left Atrial Appendage Thrombus by Sex.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Influence of renal function and dose of non-vitamin K antagonist oral anticoagulants on left atrial thrombus risk in patients with atrial fibrillation. Results from the multicenter LATTEE study.

Kardiologia polska·2026
Same author

Integrated Care in Patients with Atrial Fibrillation and Optimal Medical Treatment for Heart Failure: Results from the Heart failuRe ObsErvational Study (HEROES).

Journal of clinical medicine·2025
Same author

Assessment of Pharmacotherapy Modifications During the Treatment of Episodes of Acutely Decompensated Heart Failure: The HEROES Study.

Journal of clinical medicine·2025
Same author

Pharmacotherapy in Polish patients with heart failure with reduced ejection fraction: is it optimal?

Cardiology journal·2025
Same author

Changes in Anticoagulation Treatment and Associated Resolution or Persistence of Left Atrial Thrombus: Insights from LATTEE Registry.

The American journal of cardiology·2025

Related Experiment Video

Updated: Jun 8, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Does atrial fibrillation affect plasma endothelin level?

Beata Wozakowska-Kapłon1, Radosław Bartkowiak, Grazyna Janiszewska

  • 11st Clinical Department of Cardiology, Swietokrzyskie Centre of Cardiology, Kielce, Poland. bw.kaplon@poczta.onet.pl

Cardiology Journal
|September 25, 2010
PubMed
Summary
This summary is machine-generated.

Persistent atrial fibrillation (AF) does not alter endothelin-1 (ET-1) levels in patients without heart failure. Cardioversion also showed no significant impact on ET-1 concentrations.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

Related Experiment Videos

Last Updated: Jun 8, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

Area of Science:

  • Cardiology
  • Vascular Biology
  • Biochemistry

Background:

  • Atrial fibrillation (AF) is linked to endothelial dysfunction.
  • Endothelin-1 (ET-1) is a key mediator of vascular tone and function.
  • Investigating ET-1 in AF may reveal insights into cardiovascular pathophysiology.

Purpose of the Study:

  • To measure plasma ET-1 concentrations in persistent AF patients.
  • To assess ET-1 levels after restoring sinus rhythm via cardioversion.
  • To determine if ET-1 predicts rhythm maintenance post-cardioversion.

Main Methods:

  • Study included 43 patients with persistent AF and normal left ventricular systolic function.
  • Blood samples collected 24 hours before and 24 hours after cardioversion.
  • Sinus rhythm maintenance assessed at 30 days post-cardioversion.

Main Results:

  • No significant difference in ET-1 levels between AF patients and controls.
  • Plasma ET-1 levels remained unchanged 24 hours post-cardioversion.
  • No correlation found between baseline ET-1 and 30-day rhythm maintenance.

Conclusions:

  • Persistent AF does not alter plasma ET-1 in patients with preserved LV function and no heart failure symptoms.
  • Cardioversion does not significantly change plasma ET-1 levels within 24 hours.
  • ET-1 is not a significant predictor of rhythm maintenance in this patient cohort.